Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: FEC-DocGemzar adjuvant chemotherapy|DRUG: FEC-Doc adjuvant chemotherapy|DRUG: Zoledronic acid i.v. 2 years|DRUG: Zoledronic acid i.v. 5 years
Sponsor: Ludwig-Maximilians - University of Munich
Collaborators: AstraZeneca|Chugai Pharma USA|Eli Lilly and Company|Novartis|Sanofi|Janssen Diagnostics, LLC